# 337-TA-1276 (us_itc)

US ITC Section 337 exclusion order (Masimo pulse-oximetry patents) led Apple to disable / redesign the blood-oxygen (SpO2) feature on US Apple Watch units from January 2024. SpO2 is not marketed as an FDA-cleared medical claim.

## Key facts

- Jurisdiction: us_itc
- Filing type: itc_exclusion_order
- Status: active
- Filing number: 337-TA-1276
- Filing date: 2021-08-13
- Decision date: 2023-10-26
- Verification posture: verified
- Cap-flag notes: Honest-absence + enforcement: SpO2 is NOT an FDA-cleared medical function; the ITC order is a patent-import matter, distinct from any FDA clearance.

## Applicant

- [Apple](/companies/apple.md)

## Covered models (1)

- [Apple Watch](/models/apple-watch.md)

## Related patent litigations (1)

_ITC-is-both seam (reciprocal): this regulatory filing is paired with its patent-litigation-layer companion. The regulatory filing tracks the exclusion order; the patent litigation tracks the infringement determination._

- [337-TA-1276](/patent-litigations/masimo-v-apple-itc-337-ta-1276.md) (itc / decided / valid and infringed)

## Sources (1)

- [https://www.usitc.gov](https://www.usitc.gov)

_Canonical URL: /regulatory-filings/usitc-337-ta-1276-apple-watch-spo2. HTML version: [/regulatory-filings/usitc-337-ta-1276-apple-watch-spo2](/regulatory-filings/usitc-337-ta-1276-apple-watch-spo2)._